Kenneth Gordon to Skin Diseases, Infectious
This is a "connection" page, showing publications Kenneth Gordon has written about Skin Diseases, Infectious.
Connection Strength
0.027
-
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct; 27(10):1252-61.
Score: 0.027